Abstract
Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.
Original language | English |
---|---|
Pages (from-to) | 604-607 |
Number of pages | 4 |
Journal | Transplantation Proceedings |
Volume | 52 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2020 Mar |
ASJC Scopus subject areas
- Surgery
- Transplantation